ACTIVE_NOT_RECRUITING

Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Plan (MAC CAP). Subjects in the Randomized cohort were randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts were receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) was to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial would provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System would be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who were not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and were also not suitable for transcatheter repair with MitraClip, would be enrolled in the Non-repairable cohort. Subjects would be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.

Official Title

Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Quick Facts

Study Start:2018-06-15
Study Completion:2028-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT03433274

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Symptomatic, moderate-to-severe or severe mitral regurgitation (MR ≥ Grade III per American Society of Echocardiography criteria), or severe mitral annular calcification (MAC), where a transcatheter therapy is deemed more appropriate than open surgery by the local site heart team.
  2. 2. NYHA Functional Classification ≥ II (if Class IV, patient must be ambulatory).
  3. 3. The local site heart team determines that the subject has been adequately treated per applicable standards for coronary artery disease (e.g., revascularization), left ventricular dysfunction (e.g., cardiac resynchronization therapy) and heart failure (e.g., GDMT). The SEC must concur that the subject has been adequately treated.
  4. 4. The local site heart team and the SEC concur on the intended study cohort for the subject.
  5. 5. Age 18 years or older at time of consent.
  6. 6. Subject has been informed of the nature of the trial and agrees to its provisions, including the possibility of randomization to the Control group, complying with trial required testing, medications, and follow-up visits, and has provided written informed consent.
  1. 1. Mitral valvular vegetation or mass.
  2. 2. Left Ventricle or Left Atrium thrombus.
  3. 3. Chest condition that prevents transapical access.
  4. 4. LVEF less than 25% assessed by the site based on a TTE obtained within 120 days prior to subject consent.
  5. 5. LVEDD \> 7.0 cm assessed by the site based on a TTE obtained within 120 days prior to subject consent.
  6. 6. Prior surgical or interventional treatment of mitral valve involving implantation of prosthetic material (e.g. valve repair or replacement, or Mitra Clip).
  7. 7. Mitral pathoanatomy and LVOT anatomy deemed not suitable for Tendyne transcatheter mitral valve implantation.
  8. 8. Aortic valve disease requiring surgery or transcatheter intervention.
  9. 9. Tricuspid valve disease requiring surgery or transcatheter intervention.
  10. 10. Severe tricuspid regurgitation or severe right ventricular dysfunction.
  11. 11. Any surgical or interventional procedure within the period of 60 days prior to or planned procedure 60 days following subject registration.
  12. 12. Implant or revision of CRT device within 90 days prior to intended subject registration.
  13. 13. Myocardial infarction within 30 days prior to intended subject registration.
  14. 14. Symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease (e.g., active ischemia) requiring stenting or CABG.
  15. 15. CVA within 6 months prior to intended subject registration.
  16. 16. Unresolved severe symptomatic carotid stenosis (\> 70% by ultrasound).
  17. 17. Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure.
  18. 18. Hypertrophic or restrictive cardiomyopathy, or constrictive pericarditis.
  19. 19. Any of the following: leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy if cannot be adequately treated.
  20. 20. History of endocarditis within 6 months of planned implant procedure.
  21. 21. Active systemic infection requiring antibiotic therapy.
  22. 22. Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anti-coagulation or antiplatelet therapy) that cannot be adequately managed medically.
  23. 23. Subjects in whom TEE is contraindicated or high risk.
  24. 24. Known hypersensitivity to nickel or titanium.
  25. 25. Subject is undergoing hemodialysis due to chronic renal failure.
  26. 26. Subject has pulmonary arterial hypertension (fixed PAS \>70mmHg). Note: If PAS \> 70mmHg, site must provide documentation PAS is not fixed in order to be eligible.
  27. 27. Subject has COPD requiring continuous home oxygen therapy or chronic outpatient oral steroid use.
  28. 28. Subjects with non-cardiac comorbidities that are likely to result in a life expectancy of less than 12 months.
  29. 29. Modified Rankin Scale ≥ 4 disability.
  30. 30. Status 1 heart transplant or prior orthotopic heart transplantation.
  31. 31. Pregnant, lactating, or planning pregnancy during the clinical investigation follow-up period.
  32. 32. Currently participating in an investigational drug or another device trial that has not reached its primary endpoint.
  33. 33. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.

Contacts and Locations

Principal Investigator

Gorav Ailawadi, MD
PRINCIPAL_INVESTIGATOR
University of Michigan
Jason Rogers, MD
PRINCIPAL_INVESTIGATOR
University of California, Davis
Kyle Brunner, PhD
STUDY_DIRECTOR
Abbott Structural Heart
Paul Sorajja, MD
PRINCIPAL_INVESTIGATOR
Allina Health System
Vinod Thourani, MD
PRINCIPAL_INVESTIGATOR
Piedmont Healthcare and the Marcus Heart Valve Center

Study Locations (Sites)

Princeton Baptist Medical Center
Birmingham, Alabama, 35211
United States
UAB University Hospital
Birmingham, Alabama, 35233
United States
Banner-University Medical Center
Phoenix, Arizona, 85006
United States
HonorHealth Scottsdale Shea Medical Center
Scottsdale, Arizona, 85258
United States
Baptist Health Medical Center
Little Rock, Arkansas, 72205
United States
Fresno Heart Hospital
Fresno, California, 93720
United States
University of Southern California University Hospital
Los Angeles, California, 90033
United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048
United States
Sutter Medical Center, Sacramento
Sacramento, California, 95816
United States
University of California - Davis Medical Center
Sacramento, California, 95817
United States
San Diego Cardiac Center
San Diego, California, 92123
United States
University of California at San Francisco
San Francisco, California, 94143
United States
Stanford Health Care
Stanford, California, 94305
United States
Los Robles Hospital and Medical Center
Thousand Oaks, California, 91360
United States
University of Colorado Hospital
Aurora, Colorado, 80045
United States
Manatee Memorial Hospital
Bradenton, Florida, 34208
United States
Morton Plant Hospital
Clearwater, Florida, 33756
United States
Delray Medical Center
Delray Beach, Florida, 33484
United States
North Florida Regional Medical Center
Gainesville, Florida, 32605
United States
Shands at the University of Florida
Gainesville, Florida, 32610
United States
Baptist Hospital of Miami
Miami, Florida, 33176
United States
Tallahassee Research Institute
Tallahassee, Florida, 32308
United States
Cleveland Clinic Florida
Weston, Florida, 33331
United States
Piedmont Heart Institute
Atlanta, Georgia, 30309
United States
Emory University Hospital
Atlanta, Georgia, 30322
United States
Wellstar Kennestone Hospital
Marietta, Georgia, 30060
United States
St. Alphonsus Regional Medical Center
Boise, Idaho, 83706
United States
Rush University Medical Center
Chicago, Illinois, 60612
United States
Advocate Christ Medical Center
Oak Lawn, Illinois, 60453
United States
Prairie Education & Research Cooperative
Springfield, Illinois, 62701
United States
St. Vincent Hospital
Indianapolis, Indiana, 46260
United States
Via Christi Regional Medical Center - St. Francis Campus
Wichita, Kansas, 67226
United States
MedStar Health Research Institute
Balitmore, Maryland, 21218
United States
University of Maryland Medical Center
Baltimore, Maryland, 21201
United States
Adventist HealthCare White Oak Medical Center
Silver Spring, Maryland, 20904
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Henry Ford Hospital
Detroit, Michigan, 48202
United States
Abbott Northwestern Hospital
Minneapolis, Minnesota, 55407
United States
Mayo Clinic
Rochester, Minnesota, 55905
United States
St. Luke's Hospital
Kansas City, Missouri, 64111
United States
St. Louis University Hospital
St Louis, Missouri, 63110
United States
The International Heart Institute of Montana
Missoula, Montana, 59802
United States
Catholic Medical Center
Manchester, New Hampshire, 03102
United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601
United States
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, 08901
United States
Newark Beth Israel Medical Center
Newark, New Jersey, 07112
United States
Albany Medical College at Albany Medical Center
Albany, New York, 12208
United States
South Shore University Hospital
Bay Shore, New York, 11706
United States
Buffalo General Hospital
Buffalo, New York, 14203
United States
New York Presbyterian Hospital/ Weill Cornell Medical Center
New York, New York, 10065
United States
Lenox Hill Hospital
New York, New York, 10075
United States
Mission Health & Hospitals
Asheville, North Carolina, 28801
United States
Carolinas Medical Center
Charlotte, North Carolina, 28203
United States
Novant Health Heart and Vascular Research Institute
Charlotte, North Carolina, 28204
United States
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219
United States
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195
United States
Oklahoma Heart Institute at Utica
Tulsa, Oklahoma, 74104
United States
Providence Heart & Vascular Institute
Portland, Oregon, 97225
United States
Allegheny General Hospital - ASRI
Pittsburgh, Pennsylvania, 15212
United States
UPMC Shadyside
Pittsburgh, Pennsylvania, 15232
United States
Medical University of South Carolina
Charleston, South Carolina, 29425
United States
Baptist Memorial Hospital
Memphis, Tennessee, 38120
United States
Centennial Medical Center
Nashville, Tennessee, 37203
United States
St. Thomas Hospital
Nashville, Tennessee, 37205
United States
Cardiothoracic & Vascular Surgeons
Austin, Texas, 78756
United States
Baylor Scott & White Heart and Vascular Hospital
Dallas, Texas, 75226
United States
Medical City Dallas Hospital
Dallas, Texas, 75230
United States
Memorial Hermann Hospital
Houston, Texas, 77030
United States
University of Virginia Medical Center
Charlottesville, Virginia, 22908
United States
Inova Fairfax Hospital
Falls Church, Virginia, 22042
United States
Swedish Medical Center - Heart & Vascular
Seattle, Washington, 98122
United States
West Virginia University Hospital
Morgantown, West Virginia, 26506
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Abbott Medical Devices

  • Gorav Ailawadi, MD, PRINCIPAL_INVESTIGATOR, University of Michigan
  • Jason Rogers, MD, PRINCIPAL_INVESTIGATOR, University of California, Davis
  • Kyle Brunner, PhD, STUDY_DIRECTOR, Abbott Structural Heart
  • Paul Sorajja, MD, PRINCIPAL_INVESTIGATOR, Allina Health System
  • Vinod Thourani, MD, PRINCIPAL_INVESTIGATOR, Piedmont Healthcare and the Marcus Heart Valve Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-06-15
Study Completion Date2028-06

Study Record Updates

Study Start Date2018-06-15
Study Completion Date2028-06

Terms related to this study

Additional Relevant MeSH Terms

  • Mitral Regurgitation
  • Mitral Insufficiency
  • Mitral Valve Insufficiency
  • Cardiovascular Diseases
  • Valve Disease, Heart
  • Heart Valve Diseases
  • Functional Mitral Regurgitation
  • Degenerative Mitral Valve Disease